IPO - NuCana plc

Form Type: 424B4

Filing Date: 2025-05-07

Corporate Action: Ipo

Type: New

Accession Number: 000119312525114453

Filing Summary: NuCana plc is offering up to 2,452,935 American Depositary Shares (ADSs) in conjunction with Series A and Series B warrants to purchase more ADSs. Each ADS represents 25 ordinary shares with a nominal value of £0.0004. The offering price of the ADSs and accompanying warrants is set at $0.6454 per ADS. The Series A warrants will have an exercise price of 125% of the combined offering price, and the Series B warrants will have an exercise price of 250%, with unique provisions allowing for a 'zero exercise price' option for Series B warrant holders. The maximum shares issuable upon warrant exercises could reach up to 474,511,844 ADSs if the zero-exercise option is utilized. The document also details provisions for adjusting exercise prices based on the ADS market performance and outlines the engagement of Laidlaw & Company (UK) Ltd. as the placement agent for the offering, which is expected to close by May 7, 2025, contingent on standard closing conditions. Investors are advised that the ADSs are listed on The Nasdaq Capital Market under the symbol 'NCNA', and highlights the regulatory framework under which the offering is made, including risks and disclaimers.

Form Type: F-1/A

Filing Date: 2025-05-02

Corporate Action: Ipo

Type: Update

Accession Number: 000119312525110310

Filing Summary: NuCana plc is filing an amendment to their Form F-1 registration statement to offer up to 12,497,768 American Depositary Shares (ADS), each representing 25 ordinary shares, alongside Series A and Series B Warrants. The offering is being conducted under reasonable best efforts, with an initial public offering price of approximately $0.5601 per ADS based on the closing price of their ADSs on April 28, 2025. The Series A Warrants allow holders to purchase one ADS at an exercise price of 125% of the combined offering price with a five-year maturity, while the Series B Warrants can be exercised at 250% of the combined offering price with a two and a half-year maturity from the initial exercise date. Additionally, the filing includes a subdivision of existing ordinary shares into new lower nominal value shares, aimed at increasing share liquidity. The company emphasizes that potential investors should consider the associated risks, including the absence of an established trading market for the Warrants and Pre-Funded Warrants, which may have liquidity implications.

Form Type: F-1

Filing Date: 2025-04-24

Corporate Action: Ipo

Type: New

Accession Number: 000119312525092131

Filing Summary: NuCana plc is a clinical-stage biopharmaceutical company focusing on enhancing cancer treatment outcomes through its proprietary ProTide technology, which aims to transform widely prescribed chemotherapy agents (nucleoside analogs) into more effective and safer medicines. The company is proposing a public offering of up to 16,049,383 American Depositary Shares (ADS), representing 401,234,575 ordinary shares, along with Series A and Series B Warrants. Each ADS will be priced at $0.81 based on recent market conditions. The Series A and Series B Warrants provide purchase rights at an exercise price of 125% of the sales price, with unique cashless and zero-exercise options designed to maximize shareholder participation without necessitating cash outlay from holders. The corporate actions taken at the general meeting include a share subdivision plan to redesignate existing shares and a resolution to authorize the board of directors to allot new shares, increasing capital flexibility. The expected date for commencement of sale is forthcoming after the registration statement becomes effective.

Form Type: DRS

Filing Date: 2025-04-04

Corporate Action: Ipo

Type: New

Accession Number: 000095012325003335

Filing Summary: NuCana plc submitted a confidential draft registration statement on Form F-1 under the Securities Act of 1933 with the SEC on April 4, 2025. The company aims to offer American Depositary Shares (ADSs) representing ordinary shares and related warrants, indicating a public offering as part of its initial public offering (IPO). The prospectus highlights the intention to sell ADSs that translate into shares at a later effective date and outlines various financial aspects including pricing and structure. The offering will involve multiple securities including ordinary shares, Series A warrants, Series B warrants, and pre-funded warrants. The expected proceeds are to be utilized in the development of their drug programs and other corporate purposes, highlighting the company's focus on enhancing treatment outcomes in cancer therapy through its proprietary ProTide technology. The document specifies the lack of established public trading for the warrants and explains the implications of the offering structure for potential investors.